Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes
- 14 February 2008
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 391 (1-2), 60-67
- https://doi.org/10.1016/j.cca.2008.02.003
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemInt. Journal of Clinical Pharmacology and Therapeutics, 2006
- Acid Suppression Therapy: Where Do We Go from Here?Digestive Diseases, 2006
- Significance of the Minor Cytochrome P450 3A IsoformsClinical Pharmacokinetics, 2006
- Hydroxylation of lansoprazole in poor metabolizers of CYP2C19British Journal of Clinical Pharmacology, 2005
- Effects of clarithromycin on lansoprazole pharmacokinetics betweenCYP2C19genotypesBritish Journal of Clinical Pharmacology, 2005
- CYP2C19 Polymorphism and Proton Pump InhibitorsBasic & Clinical Pharmacology & Toxicology, 2004
- The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux DiseaseDrugs, 2004
- STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMESDrug Metabolism and Disposition, 2003
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Comparison of IY81149 with omeprazole in rat reflux oesophagitisJournal of Autonomic Pharmacology, 2000